The company is developing a companion diagnostic to identify head and neck cancer patients most likely to benefit from Erbitux.
The company's PD-L1 IHC 28-8 pharmDx diagnostic can now be used in cases of urothelial carcinoma and squamous cell carcinoma of the head and neck.
Foundation Medicine's SmartTrials Precision Enrollment program will ID patients with HRAS mutant squamous cell carcinoma of the head and neck.
New data now suggests that evaluating PD-L2 levels might better predict response to PD-1 targeting immune-oncology drugs than current tests that only measure PD-L1.
Members of the ProfiLER trial identified actionable mutations in more than half of individuals with advanced cancers, though only a fraction received targeted therapy.
A subset of mutation-associated neoantigens appeared to be lost from lung or head and neck tumors that became resistant to anti-PD1 or anti-PD1 and anti-CLTA4 therapy.
Spokespersons from Bio-Rad noted that there appears to be an increasing number of researchers using ddPCR for methylation analyses.
Understanding whether, how, and where HPV integrates into the genome could help predict patient outcomes and make treatment decisions.
The MD Anderson researchers aim to combine computational and functional approaches to investigate genomic alterations as novel therapeutic targets.
Researchers hope to advance the technology to support an assay to help personalize oral cancer treatment by avoiding the development of mucositis.
Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.
Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.
The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.
In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.